Headline
The latest stories from AHA Today.
The Food and Drug Administration authorized for emergency use the first serology test to help identify individuals with antibodies to SARS-CoV-2 at the point of care.
The Blue Cross Blue Shield insurance group has reached a tentative settlement in an antitrust lawsuit dating back to 2012 that alleged its member companies illegally conspired to divvy up markets and avoid competing against one another, driving up customers’ prices, the Wall Street Journal reports.
The Department of Health and Human Services in a strongly worded letter to Eli Lilly calls into question recent actions by the drug manufacturer to limit 340B hospital and community clinics’ use of 340B contract pharmacy arrangements.
As health care executives and their boards face increasingly complex challenges and opportunities, the best boards are taking a much more proactive approach to their own renewal.
The House voted 359-57 to pass a continuing resolution that would generally extend current federal funding levels for health care and other programs through Dec. 11.
The Centers for Medicare & Medicaid Services announced $165 million in supplemental funding to help 33 states participating in the Money Follows the Person Medicaid demonstration transition older adults and individuals with disabilities from long-term care facilities to home and community-based…
Two clinical trials launched in April to evaluate convalescent plasma as a treatment for patients hospitalized with COVID-19 are expanding, the National Institutes of Health announced.
The Centers for Disease Control and Prevention awarded $200 million in Coronavirus Aid, Relief, and Economic Security Act funds to help states, territories and other jurisdictions prepare to distribute and administer COVID-19 vaccine.
Johnson & Johnson said that its COVID-19 vaccine candidate is moving to a global phase 3 clinical trial.
The RAND Corporation last week released the third edition of its hospital price transparency study, which once again missed the mark with its flawed methodology, writes Aaron Wesolowski, AHA vice president for policy research, analytics and strategy, in the AHA Stat Blog.